 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

SEATTLE, Sept. 22, 2023 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., Neoleukin or the Company (NASDAQ:NLTX), a biopharmaceutical company that has designed de novo protein therapeutics...

Neoleukin Therapeutics Announces 1-for-5 Reverse Stock Split

US Bancorp DE boosted its position in shares of Neoleukin Therapeutics, Inc. (NASDAQ:NLTX  Free Report) by 111.2% during the first quarter, according to the company in its most recent Form...

Neoleukin Therapeutics, Inc. (NASDAQ:NLTX) Shares Acquired by US Bancorp DE

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HCCI, CCF, SCU, NLTX SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HCCI, CCF, SCU, NLTX PR Newswire NEW YORK, Aug. 22, 2023 NEW YORK, Aug. 22, 2023 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the...

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HCCI, CCF, SCU, NLTX

Neoleukin Therapeutics, Inc. (NASDAQ:NLTX Get Free Report) Director Bros. Advisors Lp Baker acquired 1,888,800 shares of the stock in a transaction that occurred on Tuesday, August 15th. The shares were bought at an average price of $0.63 per share, with a total value of $1,189,944.00. Following the...

Neoleukin Therapeutics, Inc. (NASDAQ:NLTX) Director Acquires $1,189,944.00 in Stock

Neoleukin Therapeutics, Inc. (NASDAQ:NLTX  Get Free Report) Director Bros. Advisors Lp Baker purchased 166,942 shares of Neoleukin Therapeutics stock in a transaction that occurred on...

Insider Buying: Neoleukin Therapeutics, Inc. (NASDAQ:NLTX) Director Buys 166,942 Shares of Stock

Related Stocks: NLTX, ACAD, BGNE, INCY, MDGL, SGEN...

BAKER BROS. ADVISORS LP Reduces Stake in Neoleukin Therapeutics Inc

NEW YORK, Aug. 17, 2023 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or...

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NLTX, SCU, AMNB

SAN DIEGO, Aug. 16, 2023 (GLOBE NEWSWIRE) -- National law firm Morris Kandinov is investigating the actions of the officers and board of directors of Hanmi Financial Corporation, Carvana Co., Pegasystems Inc., and Neoleukin Therapeutics, Inc. If you are a current owner of shares of any of these ...

SHAREHOLDER ALERT: Morris Kandinov Investigating HAFC, CVNA, PEGA, and NLTX; Shareholders are Encouraged to Contact the Firm

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PRDS, CCF, NLTX, SCU SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PRDS, CCF, NLTX, SCU PR Newswire NEW YORK, Aug. 15, 2023 NEW YORK, Aug. 15, 2023 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the...

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PRDS, CCF, NLTX, SCU

NEW YORK, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the M&A Class Action Firm), a national securities firm ratedTop 50in the 2018-2021 ISS Securities Class Action Services Report and headquartered at theEmpire...

STOCKHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger - SCU, DEN, NLTX, BG

Neoleukin Therapeutics, Inc. operates as a biopharmaceutical company, which computational methods to design de novo protein therapeutics. The firm address significant medical needs in oncology, inflammation, and autoimmunity. Its lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding. The company was founded by Daniel-Adriano Silva, Carl Walkey, and Umut Ulge in December 2003 and is headquartered in Seattle, WA.

Watchers	5,134
52-Wk Low	$1.88
52-Wk High	$4.70

Market Cap	$167.72M
Volume (M)	72,858.00
52-Wk High	$4.70
52-Wk Low	$1.88

Current Price	$3.81
Prev Close	$3.75
Open	$3.58
Dividend Yield	0.00%
50-Day Moving Average	$3.56
Beta	1.24
Avg. Volume	52,385.05
PE Ratio	-4.51

52-Week High	$4.70
52-Week Low	$1.88
Market Capitalization	$167.72M
EPS	-$0.8453
Price to Book	2.11
Revenue Per Employee	N/A
Enterprise Value/EBITDA	0.60

NLTX Neoleukin Therapeutics Inc

About

Feed

News

Sentiment

Earnings

Fundamentals